Evidence map›Paper›PMID 39660276›Full record

ArticleInternational journal of MS care2024

Acceptability and Feasibility of the English Version of Elevida, a Self-Guided Online Fatigue Intervention for People With Multiple Sclerosis.

Jo Lane, Carmel Poyser, Yixuan Zhao, Robyn M Lucas, Björn Meyer, Christoph Heesen, Nicolas Cherbuin, Anne Brüstle, Susy Macqueen, Alice Richardson and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of MS care, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Jo LaneFrom the National Centre for Epidemiology and Population Health, The Australian National University, Canberra, Australian Capital Territory, Australia.ORCID https://orcid.org/0000-0002-2518-1050
Carmel PoyserFrom the National Centre for Epidemiology and Population Health, The Australian National University, Canberra, Australian Capital Territory, Australia.
Yixuan ZhaoFrom the National Centre for Epidemiology and Population Health, The Australian National University, Canberra, Australian Capital Territory, Australia.
Robyn M LucasFrom the National Centre for Epidemiology and Population Health, The Australian National University, Canberra, Australian Capital Territory, Australia.
Björn MeyerGAIA AG, Hamburg, Germany.
Christoph HeesenInstitute for Neuroimmunology and Multiple Sclerosis, Universitätskklinikum Hamburg-Eppendorf, Hamburg, Germany.
Nicolas CherbuinFrom the National Centre for Epidemiology and Population Health, The Australian National University, Canberra, Australian Capital Territory, Australia.
Anne BrüstleJohn Curtin School of Medical Research, The Australian National University, Canberra, Australian Capital Territory, Australia.
Susy MacqueenSchool of Literature, Languages and Linguistics, The Australian National University, Canberra, Australian Capital Territory, Australia.
Alice RichardsonStatistical Support Network, The Australian National University, Canberra, Australian Capital Territory, Australia.
Christian LueckMedical School, The Australian National University, Canberra, Australian Capital Territory, Australia.
Stefan M GoldInstitute for Neuroimmunology and Multiple Sclerosis, Universitätskklinikum Hamburg-Eppendorf, Hamburg, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundFatigue is common in multiple sclerosis (MS); it significantly impairs quality of life, and treatment options are limited. A randomized controlled trial of Elevida, a self-guided, online German fatigue intervention, showed significant benefit. We tested an English version of Elevida with people with MS in Australia.

methodsParticipants were volunteers with MS who self-reported at least mild fatigue (≥ 43 on the Fatigue Scale for Motor and Cognitive Functions scale), some mobility (Expanded Disability Status Scale < 8), and no or mild cognitive difficulties (≤ 32 on the Multiple Sclerosis Neuropsychological Questionnaire). Participants completed the 9-week English Elevida program, commenting on and rating its acceptability. The Chalder Fatigue Scale was completed at baseline, end-of-program, and 2 months later. We undertook qualitative (thematic analysis) and quantitative (before/after differences, tested using paired

resultsThirty-eight people with MS expressed an interest in the study; 26 were eligible; 20 began the study. Fifteen participants (75%) completed the program (mean [SD]: 58.9 [10.5] years of age, 67% women, 9 with relapsing MS, 6 with progressive MS). Over 90% of completing participants rated acceptability as good or very good, and approximately 70% found the program helpful. Three themes were identified: Positive or negative comments on program features, incorrect assumptions in program content, and personal experiences and reflections. Significant improvement (

conclusionsElevida was acceptable and effective for MS-related fatigue. Identified themes will guide further development of the program to satisfy users' sense of autonomy, competence, and relatedness.

Indexed as

cognitive behavioral therapyElevidafatigueonline intervention

Identifiers

PMID39660276
PMCPMC11628539

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.